|Elimination half-life||70 hrs|
|Excretion||79% faeces, 3% urine|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||469.95 g·mol−1|
|3D model (JSmol)|
Dacomitinib has advanced to several Phase III clinical trials. The Jan 2014 results of the first trials were disappointing, with a failure to meet the study goals. Additional Phase III trials are ongoing.
Dacomitinib was approved in the United States in 2018, in Japan in 2019 and in the European Union (EU) authorized by the European Medicines Agency (EMA) in 2019  for the treatment of non-small cell lung cancer with EGFR gene mutation.
- "Dacomitinib". NCI Drug Dictionary.
- Zosia Chustecka (January 27, 2014). "Dacomitinib Fails in Pretreated Non-small Cell Lung Cancer". Medscape.
- "Blow to Pfizer as dacomitinib fails in lung cancer trials". pmlive.com. 28 January 2014.
- "Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer". Pfizer Press Release. January 27, 2014.
- Dacomitinib Sets PFS Record in Phase III NSCLC Trial. June 2017
- Shirley, Matt (2018). "Dacomitinib: First Global Approval". Drugs. 78 (18): 1947–1953. doi:10.1007/s40265-018-1028-x. PMID 30506139.
- Dacomitinib Fact Sheet, Pfizer
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|